Get the latest news, insights, and market updates on SLNO (Soleno Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement (“ASR”) with Jefferies LLC (“Jefferies”) to repurchase $100 million of Soleno’s common stock. “These actions demonstrate our confidence in our comme Nov 11, 2025 - $SLNO
Soleno Therapeutics (SLNO) Ends 26% Lower After Q3 Earnings
We recently published 10 Stocks Left Behind Amid Wall Street Cheer. Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the worst-performing stocks on Wednesday. Soleno Therapeutics extended its losing streak to a 5th consecutive day on Wednesday, slashing 26.59 percent to close at $46.87 apiece as investors appeared to have priced in a strong earnings performance […] Nov 6, 2025 - $SLNO
Soleno Therapeutics (SLNO): Losses Accelerate 43.6% Annually, Challenging Bullish Profitability Narrative
Soleno Therapeutics (SLNO) remains unprofitable, with losses deepening at an annual rate of 43.6% over the past five years. However, analysts now forecast profitability within the next three years, supported by projected annual revenue growth of 47.3% and expected earnings increases of 62.05% per year. For investors, this rapid growth outlook and the company’s stock trading below both its estimated fair value and analyst price targets could be compelling catalysts, even as share price... Nov 6, 2025 - $SLNO
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the third quarter ended September 30, 2025 and provided an update on the U.S. launch of VYKATTM XR. Third Quarter 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three months ended September 30, 2025 was $66.0 million and the Nov 4, 2025 - $SLNO
Soleno Therapeutics to Participate in Upcoming November Conferences
REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November: Guggenheim Securities Healthcare Innovation ConferencePresentation Date: Tuesday, November 11, 2025 at 9:00 AM ETPresentation Format: Fireside ChatWebcast: Here Stifel 2025 Healthcare ConferencePresentatio Oct 28, 2025 - $SLNO
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the suc Oct 22, 2025 - $SLNO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple